tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Insmed: Data from Phase 3 ASPEN study of Brensocatib due in latter part of 2Q

Enrollment in the Phase 2 study of TPIP in patients with PH-ILD completed in November 2023; Topline data expected in 2Q 2024.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on INSM:

Disclaimer & DisclosureReport an Issue

1